News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
LEE'S PHARMACEUTICAL (00950.HK) YINROSA Approved by National Medical Products Administration
LEE'S PHARMACEUTICAL (00950.HK) announced that the National Medical Products Administration of China has approved Yinrosa for the treatment of postmenopausal women with moderate to...
Reset
Send
The window will close in 5 seconds
LEE'S PHARMACEUTICAL (00950.HK) YINROSA Approved by National Medical Products Administration
Close
Recommend
1
Positive
1
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

LEE'S PHARMACEUTICAL (00950.HK)  -0.030 (-2.419%)   announced that the National Medical Products Administration of China has approved Yinrosa for the treatment of postmenopausal women with moderate to severe symptoms of vulvovaginal atrophy (excluding urinary tract symptoms). Yinrosa is owned by Cosette Pharmaceuticals and has been licensed to LEE'S PHARMACEUTICAL. (de/d)(HK stocks quote is delayed for at least 15 mins.)



Related NewsLEE'S PHARMACEUTICAL (00950.HK) Last Year's Net Profit Down 1.2% to HKD91.94 Million; Final Dividend of HKD0.023
This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

Auto-translated by AI
View Original Text

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.